DOW JONES, A NEWS CORP COMPANY
News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services.
DOW JONES
  • Barron's
  • BigCharts
  • DJX
  • Dow Jones Newswires
  • Factiva
  • Financial News
  • Mansion Global
  • MarketWatch
  • Newsmart
  • NewsPlus
  • Private Markets
  • Risk & Compliance
  • WSJ.com
  • WSJ Pro
  • WSJ Conference
  • WSJ Video
NEWS CORP
  • Big Decisions
  • Business Spectator
  • Checkout51
  • Harper Collins
  • New York Post
  • PropTiger
  • REA
  • realtor.com
  • Storyful
  • The Australian
  • The Sun
  • The Times
ストックス600 ▲
339.41 0.46%
  日経平均 ▲
16254.45 0.00%
  米10年債 ▲
1/32 yield 1.50%
  原油 ▲
41.79 -0.33%
  ユーロ/ドル ▲
1.1136 0.04%
  ダウ平均 ▲
18352.05 -0.02%
 
Subscribe Now Sign In
The Wall Street Journal
日本 (Japan)
  • U.S.
  • Asia
  • Europe
  • India
  • América Latina
  • Brasil
  • 中国 (China)
  • 日本 (Japan)
2016年8月5日
Sections
My Journal
  • ホーム
  • 経済
  • マーケット
  • ビジネス
  • テクノロジー
  • 国際
  • 国内
  • オピニオン・社説
  • ライフ
  • バロンズ
  • SHOW ALL SECTIONS HIDE ALL SECTIONS
    • 経済
      • 金融政策ウォッチ
      • Heard on the Street
    • マーケット
      • マーケットデータ
    • テクノロジー
      • ガジェットレビュー
    • 国際
      • 北米
      • 米大統領選特集
      • アジア・オセアニア
      • 欧州
      • 中東・アフリカ
      • China's World
      • China Real Time Report
    • 国内
      • 編集長インタビュー
    • オピニオン・社説
      • オピニオ ン
      • 社説
    • ライフ
      • キャリア
      • ヘルス
    • バロンズ
      • 日本市場
      • IT注目銘柄
      • インタビュー
      • コラム
    HIDE ALL SECTIONS
Sign In
  • ホーム
  • 経済
    • 金融政策ウォッチ
    • Heard on the Street
  • マーケット
    • マーケットデータ
  • ビジネス
  • テクノロジー
    • ガジェットレビュー
  • 国際
    • 北米
    • 米大統領選特集
    • アジア・オセアニア
    • 欧州
    • 中東・アフリカ
    • China's World
    • China Real Time Report
  • 国内
    • 編集長インタビュー
  • オピニオン・社説
    • オピニオ ン
    • 社説
  • ライフ
    • キャリア
    • ヘルス
  • バロンズ
    • 日本市場
    • IT注目銘柄
    • インタビュー
    • コラム
Search
Subscribe Sign In

Auris Medical Holding AG EARS (U.S.: Nasdaq)

View All companies
  • AT CLOSE 4:00 PM EDT 08/04/16
  • $4.73 USD
  • 0.78 19.75%
  • Volume 787,229
  • AFTER HOURS 7:54 PM EDT 08/04/16
  • $4.70 -0.03 -0.63%
  • AFTER HOURS Vol 1,400
  • Volume 787,229
  • 65 Day Avg Vol 83,247
  • 1 Day Range 3.93 - 4.89
  • 52 Week Range 3.02 - 7.96 (11/16/15 - 01/06/16)
  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • YTD
  • 1 Y
  • 3 Y
  • $
  • %
Advanced Charting Compare
  • Compare to Benchmark:
  • DJIA
  • S&P 500
  • GLOBAL DOW
  • NASDAQ
  • Health Care/Life Sciences
  • Compare to
  • Open 3.99
  • Prior Close 3.95 (08/03/16)
  • 1 Day
  • EARS 19.75%
  • DJIA -0.02%
  • Russell 2K 0.09%
  • Health Care/Life Sciences -0.50%
  • Overview

News Auris Medical Holding AGEARS

    • 07/19/16
    • Press Release
    Auris Medical Secures Loan Facility of Up To $20 Million
    • Press Release
    • 07/18/16
    • Press Release
    FDA Grants Auris Medical Fast Track Designation for Keyzilen in Acute Peripheral Tinnitus
    • Press Release
    • 07/08/16
    • Press Release
    Auris Medical to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference on Tuesday, July 12
    • Press Release
    • 06/28/16
    • Press Release
    Auris Medical Completes Enrollment of Phase 3 TACTT3 Trial with Keyzilen in Acute and Post-Acute Inner Ear Tinnitus
    • Press Release
    • 06/17/16
    • Press Release
    Auris Medical Initiates ASSENT Phase 3 Trial of AM-111 for Treatment of Sudden Deafness
    • Press Release
    • 06/16/16
    • Press Release
    Auris Medical to Present at the JMP Securities Life Sciences Conference on Wednesday, June 22
    • Press Release
    • 06/14/16
    • Press Release
    Auris Medical Hosts Key Opinion Leader Event Focused on Phase 3 Program for Acute Inner Ear Tinnitus
    • Press Release
    • 06/11/16
    • Barron's
    The Perils of Workaholism
    • Barron's
    • 06/07/16
    • Press Release
    Auris Medical to Host Key Opinion Leader Event Focused on Acute Inner Ear Tinnitus and AM-101's Phase 3 Program on June 14 in New York City
    • Press Release
    • 06/02/16
    • Press Release
    Auris Medical to Present at the Jefferies 2016 Healthcare Conference on Thursday, June 9
    • Press Release
    • 05/11/16
    • Press Release
    Auris Medical Provides Business Update and Reports First Quarter 2016 Financial Results
    • Press Release
    • 10/03/14
    • MarketWatch.com
    Almost half of venture-backed IPOs this year are losers
    • MarketWatch.com
load more
Key Stock Data
?
P/E Ratio (TTM)
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period.
Earnings Per Share (TTM)
A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding.
Market Capitalization
Reflects the total market value of a company. Market Cap is calculated by multiplying the number of shares outstanding by the stock's price. For companies with multiple common share classes, market capitalization includes both classes.
Shares Outstanding
Number of shares that are currently held by investors, including restricted shares owned by the company's officers and insiders as well as those held by the public.
Public Float
The number of shares in the hands of public investors and available to trade. To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded.
Dividend Yield
A company's dividend expressed as a percentage of its current stock price.

Key Stock Data

  • P/E Ratio (TTM)
    N/A
  • EPS (TTM)
    $-0.94
  • Market Cap
    $135.60 M
  • Shares Outstanding
    34.33 M
  • Public Float
    14.19 M
  • Yield
    EARS has not issued dividends in more than 1 year.
  • Latest Dividend
    N/A
  • Ex-Dividend Date
    N/A
?
Shares Sold Short
The total number of shares of a security that have been sold short and not yet repurchased.
Change from Last
Percentage change in short interest from the previous report to the most recent report. Exchanges report short interest twice a month.
Percent of Float
Total short positions relative to the number of shares available to trade.

Short Interest (07/15/16)

  • Shares Sold Short
    537,898
  • Change from Last
    17.80%
  • Percent of Float
    3.79%
?
Money Flow Uptick/Downtick Ratio
Money flow measures the relative buying and selling pressure on a stock, based on the value of trades made on an "uptick" in price and the value of trades made on a "downtick" in price. The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades. Net money flow is the value of uptick trades minus the value of downtick trades. Our calculations are based on comprehensive, delayed quotes.

Stock Money Flow

  • Uptick/Downtick Trade Ratio
    0 2
    0.87
    Net Money Flow ($)
    -146,012

    Money flow gives a snapshot of relative buying and selling pressure in a stock. A ratio above one suggests greater buying pressure, below one suggests greater selling.

Advertisement

Competitors EARS

Company Change P/E (TTM)
CPHD

Cepheid

-0.41% -0.15 -
VRML

Vermillion Inc.

+5.38% +0.07 -
A

Agilent Technologies Inc.

-0.55% -0.26 33.93
MCUR

Macrocure Ltd.

+7.04% +0.10 -
  • More information on EARS
  • Competitor Data Provided By: capital cube

Profile EARS

Auris Medical Holding AG is a clinical-stage biopharmaceutical company that develops products for the treatment of inner ear disorders. Its AM-101 and AM-111 product candidates are used to treat acute inner ear tinnitus and acute inner ear hearing loss. The company...

Bahnhofstrasse 21
Zug Zug 6300
Switzerland

  • Website
  • Map
  • Employees 22
    Sector Pharmaceuticals
  • Sales or Revenue -
    Industry Health Care/Life Sciences
  • 1Y Sales Change -
    Fiscal Year Ends December 31 Download Reports
  • Thomas Meyer Chairman & Chief Executive Officer
  • Sven Zimmermann Chief Financial & Accounting Officer
  • Bettina Mirella M. Stubinski Chief Medical Officer
  • Andrea Braun Head-Regulatory & Quality Affairs
  • More

Research & Ratings Auris Medical Holding AGEARS

Per-Share Earnings, Actuals and Estimates

  • Quarterly
  • Annual
EARS will report FY 2016 earnings on 03/23/2017 EARS will report Q2 earnings on 08/17/2016
Actual Analyst Range Consensus
0.20 0.00 -0.20
Actual -0.35
-0.23
Actual -0.15
-0.28
Actual -0.16
-0.28
Actual -0.26
-0.23
-0.26
-0.28
Q22015 Q3 Q4 Q12016 Q2 Q3
0.50 0.00 -0.50 -1.00
Actual -0.96
-1.07
-1.01
-1.07
-0.68
FY 2015 FY 2016 FY 2017 FY 2018
Q2 2016 Estimate Trends
Current: $-0.26
1 month ago: $-0.26
3 months ago: $-0.25
Q3 2016 Estimate Trends
Current: $-0.28
1 month ago: $-0.28
3 months ago: $-0.27
FY 2016 Estimate Trends
Current: $-1.01
1 month ago: $-1.02
3 months ago: $-0.99
FY 2017 Estimate Trends
Current: $-1.07
1 month ago: $-1.07
3 months ago: $-1.02
  • More

Financials Auris Medical Holding AGEARS

  • Quarterly
  • Annual

Net Income

0
0 -3M -6M -9M -12M
Mar 2015 Jun 2015 Sep 2015 Dec 2015 Mar 2016
0
0 -80M
'12 '13 '14 '15
Mar 2016 5-quarter trend
Net Income Growth -5.99%
Sales or Revenue -
Sales or Revenue Growth -
EBITDA -7.38 M
2015 5-year trend
Net Income Growth -55.30%
Sales or Revenue -
Sales or Revenue Growth -
EBITDA -31.97 M
  • More
  • Overview

Notes & Data Providers

Real-time U.S. stock quotes reflect trades reported through Nasdaq only.

International stock quotes are delayed as per exchange requirements. Indexes may be real-time or delayed; refer to time stamps on index quote pages for information on delay times.

Quote data, except U.S. stocks, provided by SIX Financial Information.

Data is provided "as is" for informational purposes only and is not intended for trading purposes. SIX Financial Information (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Data may be intentionally delayed pursuant to supplier requirements.

All of the mutual fund and ETF information contained in this display was supplied by Lipper, A Thomson Reuters Company, subject to the following: Copyright © Thomson Reuters. All rights reserved. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Bond quotes are updated in real-time. Source: Tullett Prebon.

Currency quotes are updated in real-time. Source: Tullet Prebon.

Fundamental company data and analyst estimates provided by FactSet. Copyright FactSet Research Systems Inc. All rights reserved.

Advertisement
  • Wall Street Journal
  • 日本 (Japan)
    • U.S.
    • Asia
    • Europe
    • India
    • América Latina
    • Brasil
    • 中国 (China)
    • 日本 (Japan)
  • Subscribe NowSign In

  • WSJ Membership Benefits
  • Download WSJ Apps
  • Customer Center
  • Legal Policies
  • Subscribe
  • Sign In
  • TOP«
  • Customer Service

  • Customer Center
  • Contact Us
  • About Houjin Subscribing
  • 学生割引購読
  • About Us
  • Ads

  • About Ads
  • Tools & Features

  • iPhone App
  • iPad App
  • Android App
  • Newsletter
  • About Japanese Blog Parts
  • More

  • Events
  • Jobs at WSJ
    • Facebook
    • Twitter
    • Google+
    • YouTube
    • Podcasts
    • Snapchat
    • GooglePlay
    • AppStore
    • Windows10
  • Dow Jones Products
  • Barron's
  • BigCharts
  • DJX
  • Dow Jones Newswires
  • Factiva
  • Financial News
  • Mansion Global
  • MarketWatch
  • Private Markets
  • realtor.com
  • Risk & Compliance
  • WSJ Conference
  • WSJ Pro Central Banking
  • WSJ Video
  • WSJ Wine
  • BallBall
  • Privacy Policy
  • Cookie Policy
  • Tokusyo
  • Data Policy
  • Subscriber Agreement & Terms of Use
  • Copyright ©2016 Dow Jones & Company, Inc. All Rights Reserved.